MIRA 55
Alternative Names: MIRA-55Latest Information Update: 04 Feb 2025
Price :
$50 *
At a glance
- Originator MIRA Pharmaceuticals
- Class Analgesics; Anxiolytics; Cannabinoids; Nootropics; Small molecules
- Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Anxiety disorders; Cognition disorders
Most Recent Events
- 23 Jan 2025 MIRA Pharmaceuticals plans a IND submission for MIRA 55 in first half of 2025 (MIRA Pharmaceuticals pipeline, February 2025)
- 29 Oct 2024 MIRA 55 is available for licensing as of 29 Oct 2024. https://mirapharmaceuticals.com/about-us/
- 29 Oct 2024 Preclinical trials in Anxiety disorders in USA (PO), before October 2025